Börsipäev 23.juuni
Kommentaari jätmiseks loo konto või logi sisse
-
Ilusat Võidupüha ja jaanilaupäeva kõigile foorumlastele!
Nii nagu ikka, USA turud on täna avatud tavapärasel ajal ning hetkel on USA futuurid kauplemas kerges plussis.
Gapping up
In reaction to strong earnings/guidance:
SGH +2.1%, SNX +0.5%
Select financial names showing strength following stress tests:
DFS +2.4%, RF +1.5%, BAC +0.9%, WFC +0.8%, C +0.7%, JPM +0.6%, GS +0.6%, .
Other news:
AVEO +60.3% (Eusa Pharma received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending marketing authorisation of FOTIVDA (tivozanib))
SNCR +34.6% (Siris Capital Group affirms 12.93% active stake, delivers letter indicating that they believe they could be in a position to acquire the Company in an all-cash acquisition at $18.00/share)
CARA +10.3% (FDA has granted Breakthrough Therapy designation to I.V. CR845)
BDSI +7% (announces that Health Canada has issued a Notice of Compliance approving BELBUCA)
IDRA +6.9% ( confirmed the FDA granted orphan drug designation for IMO-2125, an agonist of endosomal Toll-like receptor 9 for the treatment of melanoma Stages IIb to IV)
JONE +3.3% ( to sell several non-core assets for up to $70 million; continues to actively market additional non-core assets)
ADHD +2.7% (conducting a process to explore and review a range of strategic alternatives)
CNAT +2% (granted orphan designation by the FDA for its compound for the treatment of primary sclerosing cholangitis)
THC +1.9% (continued strength)
HIMX +1.8% (increases annual dividend per ADS to $0.24/ADS from $0.12/ADS)
RIGL +1.4% (Rigel Pharma will present data from its FIT Phase 3 clinical program evaluating the safety and efficacy of TAVALISSE in patients with chronic or persistent immune thrombocytopenia on June 24 from 12:30 - 12:45pm (CEST) at the European Hematology Association 22nd Annual Congress)
EVH +1.4% (prices secondary offering by selling shareholders of 4.5 mln shares of common stock at $25.90 per share)
PFE +1.3% (receives Complete Response Letter from the FDA regarding the Biologics License Application for its proposed epoetin alfa biosimilar)
Analyst comments:
CBAY +4.1% (initiated with a Outperform at Oppenheimer)
AKS +4.1% (upgraded to Buy from Hold at Deutsche Bank)
X +2.9% (upgraded to Buy from Hold at Deutsche Bank)
DBVT +2.7% (initiated with a Buy at Deutsche Bank)
RH +2.2% (upgraded to Buy from Hold at Deutsche Bank )
VRTX +1.3% (upgraded to Buy from Hold at Needham)
GILD +1% (initiated with a Buy at Deutsche Bank)
BIIB +0.9% (initiated with a Buy at Deutsche Bank)
OCLR +0.8% (initiated with a Buy at DA Davidson)
SBUX +0.6% (initiated with a Overweight last night after the close at KeyBanc Capital Mkts)
Gapping down
In reaction to disappointing earnings/guidance:
BBBY -10.5%, AMSWA -7.3%, BBRY -4.2%, SONC -2.4%, FINL -2.4%
Other news:
OCUL -11.6% (names Antony Mattessich to succeed Dr. Amar Sawhney as CEO on or before September 30 )
WKHS -8.9% (entered into at the market issuance sales agreement with Cowen to offer common stock having an aggregate offering price of up to $25,000,000)
BLUE -5.8% (presents interim data from the ongoing Northstar-2 (HGB-207) Phase 3 clinical study of LentiGlobin)
CLSN -4.2% (following late surge higher after canceling its registered direct offering of common stock announced Monday, June 19)
PIR -2.5% (BBBY sympathy)
WSM -1% (BBBY sympathy)
Analyst comments:
HAIN -3% (downgraded to Neutral from Overweight at JP Morgan)
LEJU -2% (downgraded to Underweight from Neutral at JP Morgan)
USG -1.5% (initiated with a Underperform at Credit Suisse)
SKT -1.4% (downgraded to Underperform from Neutral at BofA/Merrill)
MELI -1.2% (downgraded to Neutral from Buy at Citigroup)
CAT -1.1% (downgraded to Hold from Buy at Deutsche Bank)
Briefing.com
